Altamira Therapeutics Ltd. CYTOF

Annual Quarterly

No annual revenue total was found in Altamira Therapeutics Ltd.'s SEC filings.

Altamira Therapeutics Ltd. (CYTOF) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$6.2 million. As of Dec 31, 2024 it held $998,624 in cash and investments and $361,053 in total debt.

Revenue
—
Net income
$-8.46M
Operating cash flow
$-6.11M
Free cash flow
$-6.22M
EPS
$-2.99
Dividend per share
None
Shares outstanding
4.66M
+215.5% vs prior year
Net cash
$637,571
FY 2024
Operating margin
—

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
CYTOF (OTC)
Fiscal year ends
December 31
Incorporated in
Bermuda
Headquarters
Hamilton Hm 11, Bermuda
SEC filer status
Non-accelerated filer
SEC CIK
1601936
Former names
Auris Medical Holding Ltd. (until Jul 23, 2021); Auris Medical Holding AG (until Mar 14, 2019); Auris Medical AG (until Apr 18, 2014)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Key figures

Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.

FY 2024
Dec 31, 2024
Operating income
-$6.9M
Net income
-$8.5M
Diluted EPS
-$2.99
Operating cash flow
-$6.1M
Free cash flow
-$6.2M
Total assets
$8.7M
Total liabilities
$2.1M
Stockholders' equity
$6.6M
Cash and investments
$998,624
Total debt
$361,053

Recent SEC filings

Form Description Filed Period
6-K Current report (foreign issuer) Aug 29, 2025 Jun 30, 2025
6-K Current report (foreign issuer) Jun 11, 2025 Jun 11, 2025
6-K Current report (foreign issuer) May 9, 2025 May 9, 2025
20-F Annual report (foreign issuer) Apr 30, 2025 Dec 31, 2024
6-K Current report (foreign issuer) Apr 30, 2025 Apr 30, 2025
6-K Current report (foreign issuer) Mar 10, 2025 Mar 10, 2025

All 518 Altamira Therapeutics Ltd. SEC filings

Source: SEC EDGAR filings. This is company-reported data, not investment advice.